CD8型
细胞毒性T细胞
免疫疗法
CD3型
免疫学
医学
免疫系统
细胞疗法
淋巴细胞
过继性细胞移植
自然杀伤细胞
外周血淋巴细胞
T细胞
癌症研究
细胞
生物
体外
生物化学
遗传学
作者
Zhao Sun,Liang Shi,Huagang Zhang,Yi Shao,Yu Wang,Yueh‐Jaw Lin,Xin Li,Chunmei Bai
标识
DOI:10.1016/j.clim.2010.08.012
摘要
Expanded activated autologous lymphocyte (EAAL) therapy with CD3(+)CD8(+) cytotoxic T lymphocyte and CD3(-)56(+) natural killer cell as the major effector cells is a type of adoptive cell therapy. In this study, 19 patients with metastatic tumors received EAAL therapy. Two to four weeks after the administration of EAAL cells, the subsets of CD3(+)CD8(+) T lymphocytes and CD3(-)CD56(+) natural killer cells in the peripheral blood were increased significantly in comparison with those before the therapy. The number of IFN-γ secreting cells also significantly increased after the EAAL infusion (p=0.002) and the p values for the counts of CD3(+)IFN-γ(+) lymphocytes and CD3(-)IFN-γ(+) lymphocytes were 0.006 and 0.015, respectively. Moreover, the percentage of IFN-γ producing cells of the CD3(+), CD8(+) and CD3(-) subsets after infusion were all increased significantly, which indicated that EAAL therapy was able to enrich the potentially anti-tumor cytotoxic peripheral blood lymphocytes.
科研通智能强力驱动
Strongly Powered by AbleSci AI